Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Noxopharm Ltd. ( (AU:NOX) ) has shared an update.
Noxopharm has strengthened its positioning in immunology drug development by signing a memorandum of understanding with U.S.-based Tezcat Biosciences to explore combining Sofra RNA assets with Tezcat’s targeted drug delivery system, aiming to enhance treatments for cancer and chronic inflammatory diseases. The company’s Sofra platform gained scientific validation through a widely accessed Nature Immunology paper and the conclusion of dosing in the HERACLES trial for SOF-SKN in cutaneous lupus erythematosus, while leadership continuity was underscored by the appointment of longtime Sofra champion Dr Olivier Laczka as CEO.
The clinical update highlights strong safety and tolerability from the HERACLES trial, with results to be presented later this year, supporting Noxopharm’s ambitions in a multi-billion-dollar autoimmune disease market. Alongside engagement with patient advocacy initiatives in pain and autoimmune care, these developments suggest a strategic focus on leveraging Sofra technology, expanding partnerships, and advancing pipeline programs that could create future value for patients and shareholders.
More about Noxopharm Ltd.
Noxopharm Limited is an Australian clinical-stage drug development company focused on immunology and inflammation, with a core emphasis on its Sofra RNA platform. The company is developing therapies such as SOF-SKN for autoimmune and chronic inflammatory conditions, targeting sizeable markets including cutaneous lupus erythematosus and other immune-mediated diseases.
Average Trading Volume: 187,485
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$20.28M
For a thorough assessment of NOX stock, go to TipRanks’ Stock Analysis page.